Centauri Therapeutics’ $32 Million Series A Investment

Goodwin advised BIVF, Novo and Evotec on the deal.Boehringer Ingelheim Venture Fund GmbH (“BIVF”), Novo Holdings REPAIR Impact Fund (“Novo”) and Evotec SE (“Evotec”) led the series…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Martina Bellini

Author: Martina Bellini

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here